Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reported Q2 2017 earnings this Morning, coming in at ($1.78) per share, missing Wall Street’s estimates of ($1.57) per Share. Revenue for the quarter came in at $11.30 million beating analyst estimates of $10.68 million
Analyst Coverage For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
These are 3 Hold Ratings, 8 Buy Ratings .
The current consensus rating for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is Buy (Score: 2.73) with a consensus target price of $67.25 , a potential (10.14% upside)Recent Insider Trading for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
- On 8/2/2017 David P Schenkein, CEO, sold 27,000 with an average share price of $59.95 per share and the total transaction amounting to $1,618,650.00.
- On 8/2/2017 Scott Biller, Insider, sold 23,146 with an average share price of $59.60 per share and the total transaction amounting to $1,379,501.60.
- On 7/20/2017 Lewis Clayton Jr. Cantley, Director, sold 9,000 with an average share price of $56.36 per share and the total transaction amounting to $507,240.00.
- On 7/19/2017 Lewis Clayton Jr. Cantley, Director, sold 3,500 with an average share price of $56.14 per share and the total transaction amounting to $196,490.00.
- On 7/7/2017 Scott Biller, Insider, sold 2,146 with an average share price of $55.00 per share and the total transaction amounting to $118,030.00.
- On 7/3/2017 David P Schenkein, CEO, sold 3,000 with an average share price of $51.18 per share and the total transaction amounting to $153,540.00.
Recent Trading for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares of Agios Pharmaceuticals, Inc. closed the previous trading session at 56.48 down -4.58 -7.50% with 637,741 shares trading hands.